stockportfolio.pro
Stocks / ASTH vs HCM
ASTH vs HCM
Astrana Health, Inc. and HUTCHMED (China) Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Astrana Health, Inc. (ASTH) | HUTCHMED (China) Limited (HCM) | |
|---|---|---|
| Market cap | $1.9B | $1.8B |
| Revenue (latest FY) | $3.18B | $548.51M |
| Net income (latest FY) | $22.49M | $456.91M |
| Revenue growth (5y CAGR) | 35.9% | 8.8% |
| Net margin | 0.7% | 83.3% |
| Return on equity | 2.9% | 36.9% |
| P/E ratio | 62.6 | 4.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 3 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ASTH — free Open HCM — freeFrequently asked questions
Which is bigger, ASTH or HCM?
Astrana Health, Inc. is larger by market capitalization — $1.9B versus $1.8B.
Which grows faster, ASTH or HCM?
Over the last five fiscal years, Astrana Health, Inc. grew revenue faster — 35.9%/yr versus 8.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.